# Pergoveris FD and Liquid China BE Study

> **NCT04899193** · PHASE1 · COMPLETED · sponsor: **Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany** · enrollment: 72 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Pergoveris FD
- **DRUG:** Pergoveris Liquid
- **DRUG:** Gonal-f
- **DRUG:** Luveris

## Key facts

- **NCT ID:** NCT04899193
- **Lead sponsor:** Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-08
- **Primary completion:** 2022-05-28
- **Final completion:** 2022-05-28
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2022-06-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04899193

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04899193, "Pergoveris FD and Liquid China BE Study". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT04899193. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*